#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc

• https://twitter.com/Yuz6Yusof/status/1801548527299867135/photo/1

➡️OP0127- Can we predict who will get persistently active disease in people with palindromic rheumatism (PR)? 📊Cohort of 161 PR ❗️Predictive factors: Female gender, CCP, RF, >40yo, smoking & interval between flares of <1m ➡️ may be used to risk stratify @RheumNow #EULAR2024

beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0

• https://twitter.com/drpnash/status/1801547448709414948/photo/1

Différent stages of RA with disease progression. McInnes M #EULAR2024 @RheumNow https://t.co/iKpggGYU0k

• https://twitter.com/synovialjoints/status/1801546516101742753/photo/1

#EULAR2024 OP0256 Phase 2 RCT ReSScue data of fecal microbiota transplantation did not meet primary endpoint (bloating & diarrhoea) in scleroderma. How about impact on faecal incontinence symptoms? This improved throughout 20wks. Could be due improved stool consistency @RheumNow https://t.co/1t7d3M5S4Z

• https://twitter.com/Yuz6Yusof/status/1801545366212411600/photo/1
• https://twitter.com/Yuz6Yusof/status/1801545366212411600/photo/1

The fracture risk with glucocorticoids is dose dependent. Lems W #EULAR2024 @RheumNow https://t.co/TGjKu1vfXx

• https://twitter.com/synovialjoints/status/1801542929921568961/photo/1

#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo

• https://twitter.com/Yuz6Yusof/status/1801347418086326323/photo/1

PsA: one composite index that does it all cDAPSA + Investigator’s Global Assessment (IGA) of PSO Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA 88% sensitivity & specificity in DISCOVER-1 & 2 trial data #EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC

• https://twitter.com/AurelieRheumo/status/1801513887650435431/photo/1

🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer 38 PSO patients w/ arthralgia Correlation PET/CT SUVmax, TJC & tender enthesis count 68Ga-FAPI-04 uptake = higher risk developing PsA 6mo Shows signs of inflammation before MSUS! #EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn

• https://twitter.com/AurelieRheumo/status/1801509983638507885/photo/1

Leflunomide for #PMR? ✅ #Leflunomide FAR more effective than #MTX in #polymyalgia #rheumatica V fast withdrawal of #prednisone #LEF ~4 to 5 months #MTX 30 mos! ⬇️flares w LEF 😮 #EULAR2024 @RheumNow @eular_org @SebaUltraTrail https://t.co/2hk0yMH6gY

• https://twitter.com/Janetbirdope/status/1801533348843573456/photo/1
• https://twitter.com/Janetbirdope/status/1801533348843573456/photo/1

Some of these drugs dont seem to work in all of knee OA. I guess its really difficult to tease out different subtypes. Subgroup analysis from a Phase 3 intraarticular JTA-004 injection at #EULAR2024 abst#Op0305 @RheumNow https://t.co/jbkLYyl93e

• https://twitter.com/bella_mehta/status/1801555631297437929/photo/1
• https://twitter.com/bella_mehta/status/1801555631297437929/photo/1
• https://twitter.com/bella_mehta/status/1801555631297437929/photo/1
• https://twitter.com/bella_mehta/status/1801555631297437929/photo/1

🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry ➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs ➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL @RheumNow #EULAR2024

Check point inhibitors may cause bone loss and fractures. Lems W #EULAR2024 @RheumNow https://t.co/rf1AU60Eah

• https://twitter.com/synovialjoints/status/1801541693193306462/photo/1